Amgen (AMGN) reported second quarter 2014 earnings of $2.37 per share, well above the Consensus Estimate of $1.99 and the year-ago earnings of $1.88. Total revenues increased 11% to $5,180 million in the second quarter of 2014, beating the Consensus Estimate of $4,875 million. Including one-time items, second quarter earnings increased 22% to $2.01 per share. Second quarter total product revenues increased 8% from the … Continue reading Active Biotech Stock: Amgen Posts Q2 Earnings, Dominates News

Vertex Pharmaceuticals Inc.’s (VRTX) second-quarter 2014 loss came in at 79 cents per share (including stock-based compensation expense), much wider than the loss of 21 cents reported in the year-ago quarter. Second quarter 2014 loss was also wider than the Consensus Estimate of a loss of 74 cents. Excluding the impact of stock-based compensation expense, second quarter 2014 loss was 61 cents per share as … Continue reading Biotech Stock to Watch: Vertex Pharma. Posts Q2 Results

In an impressive piece of news on the Stock Market, Celgene (CELG) reported second-quarter 2014 earnings (including stock-based compensation expenses) of 80 cents per share, which surpassed the Market Consensus Estimate by 3 cents. The company’s earnings were 70 cents per share in the year-ago quarter. Figures have been adjusted to reflect the two-for-one stock split effective last month. Investors were not pleased with the … Continue reading Biotech Stock Focus: Celgene Beats Q2 Estimates With Strong Showings

AbbVie Inc (ABBV) reported second quarter 2014 earnings of 82 cents per share, unchanged from the year-ago earnings but surpassing the Consensus Estimate of 76 cents. Revenues increased 5% to $4.926 billion in the second quarter of 2014, surpassing the Consensus Estimate of $4.671 billion. Results were boosted by Humira’s strong performance. Including one-time items, second quarter 2014 earnings came in at 68 cents per … Continue reading Biotech Stock in Focus: Abbvie Q2 Earnings Impress Due to Humira Sales

Shares of Puma Biotechnology, Inc (PBYI) soared significantly after the company reported positive top-line results from the phase III trial on pipeline candidate, neratinib (PB272). Puma Biotech is evaluating neratinib for the extended adjuvant treatment of breast cancer. The phase III trial, ExteNET,(n=2821) is a double blind trial, which is evaluating neratinib versus placebo after adjuvant treatment with Roche’s (RHHBY) Herceptin in women suffering from … Continue reading Biotech Stock in News: Puma Biotech Surges on Positive Results on Neratinib

There is no holding back Gilead Sciences’ (GILD – Analyst Report) hepatitis C virus (HCV) drug Sovaldi. The drug continued its exceptional performance in the second quarter of 2014, helping the company to beat the Consensus Estimate in Q2 on both revenues and earnings. The biopharmaceutical company’s second quarter adjusted earnings (including stock based compensation expenses) was of $2.32 per share. The second quarter 2014 … Continue reading Biotech Stock Top News: Gilead’s Q2 Earnings